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Clinical Investigation  
 Complications: 1 
• The major long-term complications relate to 
damage to blood vessels with the risk 
of "macrovascular" diseases development 
(coronary artery disease, stroke, peripheral 
vascular disease)  
https://en.wikipedia.org/wiki/Diabetes_mellitus#Signs_and_symptoms 
Clinical Investigation  
 Complications: 2 
• The primary complications of diabetes due to 
damage in small blood vessels include damage to 
the eyes, kidneys, and nerves (diabetic retinopathy 
that result in gradual vision loss 
and blindness, diabetic nephropathy that leads to 
chronic kidney disease,  diabetic neuropathy, 
diabetes-related foot problems (diabetic foot 
ulcers, occasionally requiring amputation),proximal 
diabetic neuropathy that causes painful muscle 
wasting and weakness, cognitive deficit   
https://en.wikipedia.org/wiki/Diabetes_mellitus#Signs_and_symptoms 
Clinical Investigation  
 Complications: 3 
http://www.imhealth.com/wp-content/uploads/2015/02/complications.jpg 
TEST - 1 
R.R. is a 62 year-old man who was initially seen because of gangrene of 
the foot and shortness of breath. He had been told that he had a mild 
case of diabetes 4-5 years ago. He has seen physicians intermittently, 
and is unaware of what his glucose regulation has been. He denies 
polydipsia or polyuria. About 6 months ago, he injured his right foot, 
and it has failed to heal. One year ago, he was admitted to a coronary 
care unit for shortness of breath. A myocardial infarction was said to 
have been ruled out. He stopped smoking 15 years ago. Current 
medications were 5 mg glyburide twice a day.  
http://www.meddean.luc.edu/lumen/meded/mech/cases/case17/Case_f.htm 
TEST - 2 
Physical examination showed weight of 170 pounds, height 5'9", and 
blood pressure 180/105 mmHg. He had bilateral engorged jugular veins 
and inspiratory moist rales. Dorsalis pedis and posterior tibial pulses 
were absent bilaterally. The right foot was erythematous, and several 
toes had areas of dry gangrene (2nd toe, lateral aspects of big toe, 5th 
toe), no tenderness and no pus. Sensation in the right foot was 
diminished. Laboratory data were plasma glucose 237 mg/dl, total 
serum cholesterol 266 mg/dl (desirable: <200 mg/dl), high-density 
lipoprotein (HDL) cholesterol 29 mg/dl (desirable: >35 mg/dl), 
triglycerides 285 mg/dl (desirable: <200 mg/dl), and HbA1c 8.9% 
(normal <6.2%).  
http://www.meddean.luc.edu/lumen/meded/mech/cases/case17/Case_f.htm 
TEST - 3 
The patient was educated, taught self-monitoring of blood glucose, 
instructed in diet, given treatment for his congestive heart failure, which 
controlled his dypsnea, and had his glyburide increased to 10 mg in the 
morning and 5 mg at night. Two years ago, he had a femoral-popliteal 
bypass and removal of two toes. Repeat blood studies showed only a 
modest improvement in glycemic control (plasma glucose levels 180-210 
mg/dl). Fasting triglycerides were 240 mg/dl, HDL cholesterol was 33 
mg/dl, and total cholesterol was 286 mg/dl.  
http://www.meddean.luc.edu/lumen/meded/mech/cases/case17/Case_f.htm 
TEST - 4 
Questions 
 
1. What are the chronic complications of diabetes in this case?2. Why 
was a serious complication such as gangrene preceded by minimal 
symptoms of diabetes? 
2. Identify the cardiovascular and microvascular risk factors in the 
history, physical examination, and laboratory data in this patient. 
3. What are the management objectives from what you know about 
the clinical conditions of this patient? 
  
  
 
http://www.meddean.luc.edu/lumen/meded/mech/cases/case17/Case_f.htm 
Clinical Investigation  
 Complications: Peripheral Neuropathy 1 
• Numbness or reduced ability to feel pain or 
temperature changes 
• A tingling or burning sensation 
• Sharp pains or cramps 
• Increased sensitivity to touch — for some 
people, even the weight of a bed sheet can be 
agonizing  
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Peripheral Neuropathy 2 
•  Muscle weakness 
• Loss of reflexes, especially in the ankle 
• Loss of balance and coordination 
• Serious foot problems, such as ulcers, 
infections, deformities, and bone and joint pain 
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Autonomic Neuropathy 1 
• A lack of awareness that blood sugar levels are 
low (hypoglycemia unawareness) 
• Bladder problems (urinary tract infections, urinary 
retention or incontinence) 
• Constipation and/or uncontrolled diarrhea 
• Slow stomach emptying (gastroparesis), leading to 
nausea, vomiting, bloating and loss of appetite 
• Difficulty swallowing 
• Erectile dysfunction in men  
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Autonomic Neuropathy 1 
• Vaginal dryness and other sexual difficulties in 
women 
• Increased or decreased sweating 
• Inability of your body to adjust blood pressure and 
heart rate, leading to sharp drops in blood 
pressure after sitting or standing that may cause 
you to faint or feel lightheaded 
• Problems regulating body temperature 
• Changes in the way eyes adjust from light to dark 
• Increased heart rate at rest 
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Radiculoplexus Neuropathy 1 
• Radiculoplexus neuropathy (diabetic 
amyotrophy, femoral neuropathy, proximal 
neuropathy) affects nerves in the thighs, 
hips, buttocks or legs more common in 
older adults with type 2 DM  
• Symptoms are usually on one side of the 
body, though in some cases symptoms may 
spread to the other side  
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Radiculoplexus Neuropathy 2 
• Most people improve at least partially over 
time, though symptoms may worsen before 
they get better 
• This condition is often marked by: 
• Sudden, severe pain in hip and thigh or buttock 
• Eventual weak and atrophied thigh muscles 
• Difficulty rising from a sitting position 
• Abdominal swelling, if the abdomen is affected 
• Weight loss 
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Mononeuropathy 1 
• Mononeuropathy (focal neuropathy) 
involves damage to a specific nerve and it's 
most common in older adults 
• Mononeuropathy can cause severe pain, it 
usually doesn't cause any long-term 
problems  
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Mononeuropathy 2 
• Signs and symptoms depend on which 
nerve is involved and may include: difficulty 
focusing eyes, double vision or aching 
behind one eye; paralysis on one side of the 
face (Bell's palsy); pain in a shin or foot; 
pain in a lower back or pelvis;  pain in the 
front of a thigh, pain in the chest or 
abdomen  
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Mononeuropathy 3 
• Sometimes mononeuropathy occurs when a 
nerve is compressed, e.g.  carpal tunnel 
syndrome  (numbness or tingling in fingers 
or hand, especially in thumb, index finger, 
middle finger and ring finger, etc.).  
http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/symptoms/con-20033336 
Clinical Investigation  
 Complications: Diabetic Foot Ulcers 1 
• Diabetic foot ulcers  occur 
in 15% of people with DM 
and precedes 84% of all 
diabetes-related lower-
leg amputations   
https://www.cs.montana.edu/webworks/projects/stevesbook/artifacts/images/chapter_003/Section002/DiabeticFootUlcer350w.jpg http://emedicine.medscape.com/article/460282-overview 
Clinical Investigation  
 Complications: Diabetic Foot Ulcers 2 
• Risk factors are diabetic 
neuropathy, peripheral 
vascular disease, cigarette 
smoking, poor glycemic 
control, previous foot 
ulcerations or amputations, 
diabetic nephropathy, 
and ischemia of small and 
large blood vessels   
https://www.cs.montana.edu/webworks/projects/stevesbook/artifacts/images/chapter_003/Section002/DiabeticFootUlcer350w.jpg http://emedicine.medscape.com/article/460282-overview 
Clinical Investigation  
 Complications: Diabetic Foot Ulcers 3 
• Diabetic foot lesions are 
responsible for more 
hospitalizations than any 
other complication of 
diabetes 
https://www.cs.montana.edu/webworks/projects/stevesbook/artifacts/images/chapter_003/Section002/DiabeticFootUlcer350w.jpg http://emedicine.medscape.com/article/460282-overview 
Diagnosis  
World Health Organization (WHO) Criteria 
Methods and criteria for diagnosing diabetes 
• Diabetes symptoms (e.g. polyuria, polydipsia and 
unexplained weight loss for Type 1) plus: 
– a random venous plasma glucose concentration ≥ 11.1 mmol/l or 
– a fasting plasma glucose concentration ≥ 7.0 mmol/l (whole 
blood ≥ 6.1 mmol/l) or 
– two hour plasma glucose concentration ≥ 11.1 mmol/l two hours 
after 75g anhydrous glucose in an oral glucose tolerance test 
(OGTT). 
• With no symptoms diagnosis should not be based on a 
single glucose determination but requires confirmatory 
plasma venous determination.   
https://www.diabetes.org.uk/About_us/What-we-say/Diagnosis-ongoing-management-monitoring/New_diagnostic_criteria_for_diabetes/ 
Diagnosis  
World Health Organization (WHO) Criteria 
Gestational diabetes 
The criteria for diagnosing gestational diabetes is 
different.  Gestational diabetes should be diagnosed 
if the woman has either: 
• a fasting plasma glucose level of 5.6mmol/l or 
above or 
• a 2-hour plasma glucose level of 7.8mmol/l or 
above. 
https://www.diabetes.org.uk/About_us/What-we-say/Diagnosis-ongoing-management-monitoring/New_diagnostic_criteria_for_diabetes/ 
Diagnosis  
World Health Organization (WHO) Criteria 
Glycated Hemoglobin A1c (HbA1c) testing to 
diagnose diabetes 
• An HbA1c of 48mmol/mol (6.5%) is recommended 
as the cut off point for diagnosing diabetes   
• In patients without symptoms of diabetes the 
laboratory venous HbA1c should be repeated, and 
if the second sample is <48mmol/mol (6.5%) the 
person should be treated as at high risk of diabetes 
and the test should be repeated in 6 months or 
sooner if symptoms develop  
https://www.diabetes.org.uk/About_us/What-we-say/Diagnosis-ongoing-management-monitoring/New_diagnostic_criteria_for_diabetes/ 
Diagnosis  
Glycated hemoglobin (Hb A1C) test 
• Glycated hemoglobin (Hb A1C) test indicates average 
blood sugar level for the past two to three months 
• Glycated hemoglobin (Hb A1C) test measures the 
percentage of blood sugar attached to hemoglobin, 
the oxygen-carrying protein in red blood cells 
• The higher blood sugar levels, the more hemoglobin 
patient will have with sugar attached 
• An Hb A1C level of 6.5 percent or higher on two 
separate tests indicates that patient have diabetes  
http://www.mayoclinic.org/diseases-conditions/diabetes/basics/tests-diagnosis/con-20033091 
Diagnosis  
World Health Organization (WHO) Criteria 
https://en.wikipedia.org/wiki/Diabetes_mellitus#Signs_and_symptoms 
Condition 
2 hour glucose Fasting glucose Hb A1C 
mmol/l(mg/dl) mmol/l(mg/dl) mmol/mol DCCT % 
Normal <7.8 (<140) <6.1 (<110) <42 <6.0 
Impaired fasting 
glycaemia 
<7.8 (<140) 
≥6.1(≥110) & 
<7.0(<126) 
42-46 6.0–6.4 
Impaired 
glucose 
tolerance 
≥7.8 (≥140) <7.0 (<126) 42-46 6.0–6.4 
Diabetes 
mellitus 
≥11.1 (≥200) ≥7.0 (≥126) ≥48 ≥6.5 
Management  
 Organization of DM Care: 1 
• All people with DM should be receiving 
continuing preventative care through 
education and medical interventions 
• All people with DM need annual 
surveillance to detect early on the 
development of late tissue damage, and 
where this is detected access to protocols 
and resources for its management   
https://www.staff.ncl.ac.uk/philip.home/iddmch1.htm#Delivery 
Management  
 Organization of DM Care: 2 
• All people with DM should have 
continuing access to DM team, for help in 
management and social difficulties arising 
from DM 
• All people with DM have a role in the 
development and organization of the 
service of which they are a part   
https://www.staff.ncl.ac.uk/philip.home/iddmch1.htm#Delivery 
Management  
 Organization of DM Care: 3 
• All DM management teams should have 
an active policy of quality improvement   
• Appropriate special care should be offered 
to those with special needs, including 
pregnant women. 
https://www.staff.ncl.ac.uk/philip.home/iddmch1.htm#Delivery 
Management  
 Diet and Activity: 1 
• All patients on insulin should have a 
comprehensive diet plan, created with the help 
of a professional dietitian, that includes the 
following: 
• A daily caloric intake prescription 
• Recommendations for amounts of dietary 
carbohydrate, fat, and protein  
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
 Diet and Activity: 2 
• Instructions on how to divide calories between 
meals and snacks 
• Exercise is also an important aspect of diabetes 
management. Patients should be encouraged to 
exercise regularly  
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
 Self-Monitoring in Glycemic Control: 1 
• Benefits of tight glycemic control include not 
only continued reductions in the rates of DM 
complications but also in overall mortality 
• Optimal DM control requires frequent self-
monitoring of blood glucose levels, which 
allows rational adjustments in hypoglycemic 
medications  
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
 Self-Monitoring in Glycemic Control: 2 
• All patients should learn how to self-monitor 
and record their blood glucose levels with 
home analyzers and adjust their hypoglycemic 
medications doses accordingly 
• Real-time continuous monitoring of glucose—
using continuous glucose monitors (CGMs)—
can help patients improve glycemic control  
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
 Continuous Glucose Monitors (CGMs)  
Continuous glucose monitors 
(CGMs)contain subcutaneous 
sensors that measure 
interstitial glucose levels 
every 1-5 minutes, providing 
alarms when glucose levels 
are too high or too low or are 
rapidly rising or falling  
 
https://www.medtronicdiabetes.ca/sites/canada/www.medtronicdiabetes.ca/files/styles/245px_list_image/public/veoml-on-body_1.jpg?itok=CIC_4ZHY 
http://blog.amal.net/wp-content/uploads/2010/02/glucose_monitoring.jpg http://emedicine.medscape.com/article/117739-overview#showall 
Implantable 
Management  
 Glucose Meters  
http://diabetespharmacist.wp.lexblogs.com/wp-content/uploads/sites/346/2013/09/Blood-glucose-monitors.jpg 
https://upload.wikimedia.org/wikipedia/commons/6/62/Blausen_0301_Diabetes_GlucoseMonitoring.png 
Implantable 
Management 
 Objectives of DM Management  
https://www.staff.ncl.ac.uk/philip.home/iddmch1.htm#Delivery 
Management  
 Insulin: Therapy 1 
• Patients with type 1 DM require lifelong 
insulin therapy 
• Most require 2 or more injections of insulin 
daily, with doses adjusted on the basis of 
self-monitoring of blood glucose levels 
• Insulin replacement is accomplished by 
giving a basal insulin and a preprandial 
(premeal) insulin  
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
 Insulin: Therapy 2 
• The basal insulin is either long-acting 
(glargine or detemir) or intermediate-acting 
(NPH) 
• The preprandial insulin is either rapid-
acting (lispro, aspart, insulin inhaled, or 
glulisine) or short-acting (regular)  
http://emedicine.medscape.com/article/117739-overview#showall 
Management  
 Insulin: Types 1 
The commonly used types of insulin in DM 
patients  are:  
• fast-acting which begin to work within 5 to 15 
minutes and are active for 3 to 4 hours  
• short-acting which begins working within 30 
minutes and is active about 5 to 8 hours   
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
 Insulin: Types 2 
The commonly used types of insulin in DM 
patients  are:  
• intermediate-acting, includes NPH insulin which 
begins working in 1 to 3 hours and is active 16 to 
24 hours; long acting, which begins working 
within 1 to 2 hours and continue to be active, 
without major peaks or dips, for about 24 hours, 
although this varies in many individuals  
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
 Insulin: Types 3 
The commonly used types of insulin in DM 
patients  are:  
• ultra-long acting,  which begins working within 30–
90 minutes, and continues to be active for greater 
than 24 hours 
• combination insulin products, which include a 
combinations of either fast-acting or short-acting 
insulin with a longer acting insulin   
 
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
 Insulin: Methods of Administration 1 
• Insulin is usually taken as subcutaneous 
injections by single-use syringes with needles, 
an insulin pump, by repeated-use insulin 
pens with needles, or by use an injection 
port in conjunction with syringes  
• Administration schedules often attempt to 
mimic the physiologic secretion of insulin by 
the pancreas   
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
 Insulin: Methods of Administration 2 
• Insulin pumps are a reasonable solution for 
some, and advantages are better control over 
background or 'basal' insulin dosage, bolus 
doses calculated to fractions of a unit, and 
calculators in the pump that may help with 
determining 'bolus' infusion dosages 
• Insulin pumps may be like 'electrical injectors' 
attached to a temporarily 
implanted catheter or cannula.  
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
 Insulin: Insulin Pump  
http://images.dailytech.com/nimage/21235_large_Insulin-Pump.jpg http://blogs.discovermagazine.com/d-brief/files/2013/06/insulin-pump.jpg 
Management  
 Insulin: Dosage and Timing 1  
• One international unit of insulin (1 IU) is 
defined as the "biological equivalent" of 
34.7 μg pure crystalline insulin 
• The unit of measurement used in insulin 
therapy is not part of the International 
System of Units (abbreviated SI) which 
is the modern form of the metric system  
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
 Insulin: Dosage and Timing 2 
• Instead the pharmacological 
international unit (IU) is defined by 
the WHO Expert Committee on 
Biological Standardization  
https://en.wikipedia.org/wiki/Insulin_(medication) 
Management  
 Insulin: Multiple Daily Injections  
http://dtc.ucsf.edu/images/graphs/graph_intense_type1.gif 
Management  
(Insulin: Sample regimen using insulin NPH and regular insulin  
https://en.wikipedia.org/wiki/Insulin_(medication) 
 
before breakfast 
before lunch before dinner at bedtime 
NPH dose 12 units 6 units 
regular insulin dose if 
fingerstick 
glucose is (mg/dl) 
[mmol/L]: 
  
70-100       [3.9-5.5] 4 units 4 units 
101-150     [5.6-8.3] 5 units 5 units 
151-200     [8.4-11.1] 6 units 6 units 
201-250     [11.2-13.9] 7 units 7 units 
251-300     [14.0-16.7] 8 units 1 unit 8 units 1 unit 
>300         [>16.7] 9 units 2 units 9 units 2 units 
Management  
 Insulin Administration  
http://www.chkd.org/Images/W2G%20Health%20Library/diabetes6.jpg 
TEST - 1                
A 19-year old marine was brought to the infirmary after passing out 
during basic training. He had repeatedly complained of severe 
weakness, dizziness, and sleepiness during the preceding 4 weeks of 
boot camp. In a previous episode 3 weeks earlier, he had drowsiness 
and generalized tiredness, and was brought to the infirmary, where after 
IV administration of saline, he was returned to duty with the diagnosis 
of dehydration. Upon questioning, he reported unquenchable thirst, and 
the repeated need to urinate. Although he ate all of his rations as well 
as whatever he could get from his fellow trainees, he had lost 19 
pounds. (Baseline body weight was 150 pounds, height 5'8"). On the last 
day, he complained of vague abdominal pain, which was worse on the 
morning of admission. He had vomited once. During examination, he 
was oriented but tachypneic. He appeared pale, dehydrated with dry 
mucous membranes, and poor skin turgor.   
http://www.chkd.org/Images/W2G%20Health%20Library/diabetes6.jpg 
TEST - 2                
His respiratory rate was 36/minute with deep, laborious breathing; his 
heart rate was 138/minute regular, and his blood pressure was 90/60. 
His chest was clear, heart tones were normal. There was an ill-defined 
generalized abdominal tenderness, which was otherwise soft to 
palpation and showed no rebound. There was a generalized muscular 
hypotonia; his deep tendon reflexes were present but very weak. 
Laboratory, on admission, showed glucose of 560 mg/dl, sodium 154, 
potassium 6.5, pH 7.25, bicarbonate 10 mM/liter, chloride 90, BUN 
(blood urea nitrogen) 38 mg/dl, creatinine 2.5 mg/dl. (Normal values: 
glucose, 70-114 mg/dl; Na = 136-146; K, 3.5-5.3; Cl, 98-108; CO2, 20-32 
[all in mM/l]; BUN, 7-22mg/dl; creatinine, 0.7-1.5 mg/dl). A urine 
sample was 4+ for glucose and had "large" acetone. HbA1c was 14% 
(n=4-6.2%). Serum acetone was 4+ undiluted, and still positive at the 
4th dilution. Beta-Hydroxybutyrate level was 20 millimols/liter 
(normal=0.0-0.3 mM/l).  
 
http://www.chkd.org/Images/W2G%20Health%20Library/diabetes6.jpg 
TEST - 3                
He was treated with insulin and saline I.V. By the 4th hour of treatment, 
potassium chloride was added to the IV at a rate of 15 mEq/hour. 
Sixteen hours later, he was active, alert, well hydrated and cheerful, 
indicating he felt extremely well. He requested that his IV be 
discontinued. His physician decided to switch his insulin to 
subcutaneous injections and to start a liquid diet. He was later put on a 
diabetes maintenance diet and treated with one injection of Human 
Lente insulin in the morning. Although his blood sugars the next 
morning were 100-140 mg/dl, he had frequent episodes of 
hypoglycemia during the day, and his HbA1c was 9%. Eventually, he was 
put on 3 injections of regular insulin/day, and a bedtime intermediate 
duration (Lente) insulin.  
http://www.chkd.org/Images/W2G%20Health%20Library/diabetes6.jpg 
TEST - 4                
Questions 
 
• Why did the patient improve after being given IV saline in his first 
admission? 
• Why was dyspnea his presenting symptom? 
• He was hyperkalemic on admission, and yet, why was potassium later 
added to the IV infusion? 
• What is the possible reason why a single injection of insulin in the 
morning failed to control his diabetes without causing 
hypoglycemia?  
http://www.chkd.org/Images/W2G%20Health%20Library/diabetes6.jpg 
Management  
 Treatment of Type 2 DM: 1  
• Individualized glycemic targets and glucose-
lowering therapies 
• Diet, exercise, and education as the foundation 
of the treatment program 
• Use of metformin as the optimal first-line drug 
unless contraindicated 
• After metformin, the use of 1 or 2 additional 
oral or injectable agents, with a goal of 
minimizing adverse effects if possible  
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management  
 Treatment of Type 2 DM: 2  
• Ultimately, insulin therapy alone or with other 
agents if needed to maintain blood glucose 
control 
• Where possible, all treatment decisions should 
involve the patient, with a focus on patient 
preferences, needs, and values 
• A major focus on comprehensive cardiovascular 
risk reduction 
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management  
 Oral Antihyperglycemic Drugs: Biguanides  
• Biguanides decrease hepatic glucose production, 
decrease gastrointestinal glucose absorption, and 
increase target cell insulin sensitivity 
• Example: Metformin 
• Contraindications: Metabolic acidosis with or without 
coma, abnormal creatinine clearance from any cause 
including diabetic ketoacidosis, shock, acute 
myocardial infarction, septicemia, renal disease 
(serum creatinine level ≥1.5 mg/dL in males or ≥1.4 
mg/dL in females), lactation, radiologic contrast study 
within 48 hours 
http://emedicine.medscape.com/article/2172160-overview 
Management  
 Oral Antihyperglycemic Drugs: Sulfonylureas  
• Sulfonylureas increase beta-cell insulin 
secretion, decrease hepatic glucose output, and 
increase insulin receptor sensitivity at 
peripheral target tissues 
• Examples: Glyburide, glipizide, glimepiride, 
tolazamide, tolbutamide 
• Contraindications: Sulfa allergy, type 1 DM, 
diabetic ketoacidosis, concomitant use 
with bosentan 
http://emedicine.medscape.com/article/2172160-overview 
TEST - 1  
P.A. is a 52-year old man who presented with a 2-week history of 
polyuria, polydipsia, polyphagia, weight loss, fatigue, and blurred vision. 
A random glucose test performed 1 day before presentation was 352 
mg/dl. The patient denied any symptoms of numbness, tingling in hands 
or feet, dysuria, chest pain, cough or fevers. He had no prior history of 
diabetes and no family history of diabetes. 
Admission non-fasting serum glucose 248 mg/dl (N=<180 mg/dl), HbA1c 
9.6% (N=4-6.1%). Electrolytes, BUN and creatinine were normal. Physical 
examination revealed weight of 180 pounds, height 5'5.5" (IBW 140-
145). The rest of the examination was unremarkable, i.e., no signs of 
retinopathy or neuropathy.  
meddean.luc.edu/lumen/meded/mech/cases/case17/Case_f.htm 
TEST - 2  
The patient was taught self-monitoring of blood glucose and begun on 5 
mg glyburide once a day. He was instructed in diet (1800 cal ADA). Blood 
glucose levels ranged from 80 to 120 mg/dl within 2 weeks of starting 
glyburide, his symptoms disappeared and weight remained constant. 
During the next two months, blood glucose levels decreased to 80 
mg/dl, and glyburide was stopped. Patient did not return until one year 
later; fasting serum glucose was 190 mg/dl, and HbA1c 8%. He again 
had polyuria and nocturia. Weight was unchanged from time of 
presentation. The physician put him on 5 mg/day of glyburide. His blood 
sugar one month later remained at 180 mg/day. At this point, his 
physician decided to put him on insulin alone, 20 units/day at bedtime. 
Two weeks later, his fasting plasma glucose was 120 mg/dl.  
meddean.luc.edu/lumen/meded/mech/cases/case17/Case_f.htm 
TEST - 3  
Questions 
 
1. What are the mechanisms of blurred vision which was part of his 
initial symptoms? 
2. Are there correlations between his abnormal blood chemistries and 
his other symptoms? 
3. Why did an 1,800 calorie a day diet fail to lower his body weight? 
4. Was insulin treatment at this time the only possible option? 
 
meddean.luc.edu/lumen/meded/mech/cases/case17/Case_f.htm 
TEST 
A 52-year-old man with recently diagnosed type 2 diabetes mellitus 
comes to the physician for a follow-up examination. Physical 
examination shows no abnormalities. Laboratory studies show an 
increased hemoglobin A1c despite patient compliance with diet and 
exercise recommendations. Treatment with a sulfonylurea is started. 
Which of the following is most likely to occur in this patient?  
  
(A) Decreased entry of glucose into the muscle cells (B) Decreased 
production of glucose from the liver (C) Decreased secretion of insulin 
from the pancreas (D) Decreased speed of carbohydrate absorption 
from the intestines (E) Increased entry of glucose into the muscle cells 
(F) Increased production of glucose from the liver (G) Increased 
secretion of insulin from the pancreas (H) Increased speed of 
carbohydrate absorption from the intestines  
USMLE Step 1 Sample Test Questions A Joint Program of the Federation of State Medical Boards of the United States, Inc., and the National Board of Medical Examiners® 
Management  
 Oral Antihyperglycemic Drugs: Thiazolidinediones  
• Thiazolidinediones increase insulin receptor 
sensitivity and influence the production of gene 
products involved in lipid and glucose 
metabolism; their mechanism of action 
depends on the presence of insulin for activity 
• Examples: Pioglitazone, rosiglitazone 
• Contraindications: Hypersensitivity to product 
or components, established NYHA class III/IV 
heart failure 
http://emedicine.medscape.com/article/2172160-overview 
Management  
 Oral Antihyperglycemic Drugs: Alpha-Glucosidase Inhibitors  
• Inhibit the upper gastrointestinal enzymes that 
convert dietary starch and other complex 
carbohydrates into simple sugars, which can be 
absorbed 
• Examples: Acarbose (Precose) & Miglitol 
(Glycet) 
• Contraindications: Diabetic ketoacidosis; 
cirrhosis; inflammatory bowel disease, colonic 
ulceration, partial intestinal obstruction, 
http://emedicine.medscape.com/article/2172160-overview 
Management  
 Peptide analogs  
• Injectable Incretin mimetics as 
insulin secretagogues:  glucagon-like peptide-1 (GLP-1) 
analog  and gastric inhibitory peptide (glucose-
dependent insulinotropic peptide, GIP) analog  
• Injectable Amylin analogues that slow gastric 
emptying and suppress glucagon have all the incretins 
actions except stimulation of insulin secretion 
• Glycosurics (SGLT-2 inhibitors) block the re-uptake of 
glucose in the renal tubules, promoting loss of glucose 
in the urine  
 
 
 
https://en.wikipedia.org/wiki/Anti-diabetic_medication 
Management  
 Treatment of Gestational DM: 1  
• Diet: avoid single large meals and foods with a 
large percentage of simple carbohydrates 
• Insulin: the goal of insulin therapy during 
pregnancy is to achieve glucose profiles similar 
to those of nondiabetic pregnant women 
• Glyburide and metformin: trials have shown 
these 2 drugs to be effective, and no evidence 
of harm to the fetus has been found  
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management  
 Treatment of Gestational DM: 2  
• Management of the neonate: the employment 
of frequent blood glucose checks and early oral 
feeding (ideally from the breast) when possible, 
with infusion of intravenous glucose if oral 
measures prove insufficient. 
http://emedicine.medscape.com/article/117853-overview?pa=CgeHjeSgk%2FcDlbsbhmDMA9cE2X%2BmOE54EaA2Xw4hfL8ZpJ81sdgi18lmhYSYbGLT8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management  
 Surgery  
• A pancreas transplant is occasionally considered 
for people with type 1 DM who have severe 
complications of their disease, including end 
stage kidney disease requiring kidney 
transplantation  
• Weight loss surgery in those with obesity and 
type 2 DM is often an effective measure 
• Many are able to maintain normal blood sugar 
levels with little or no medications following 
surgery and long-term mortality is decreased  
https://en.wikipedia.org/wiki/Diabetes_mellitus#Lifestyle 
Prognosis  
• The general statistical prognosis is that 15% of 
sufferers of type 1 DM will die before the age of 
40,  sensible blood sugar control and a healthy diet 
can lead to a long life for  sufferers  
• Contracting type 2 DM in  40’s means five to 10 
years off  average life expectancy; however, as with 
the above, this is a vast improvement on recent 
years 
• As Heart Disease is the leading cause of death in 
Type 2 DM sufferers, keeping to a regime that 
minimises the risk is very much recommended  
http://www.medical1stop.com/diabetes-symptoms-causes-treatment-and-prognosis/ 
Prophylaxis 1  
• There is no known preventive measure for 
type 1 DM 
• Type 2 DM can often be prevented or delayed 
by maintaining a normal body weight, engaging 
in physical exercise, and consuming a healthful 
diet 
• Higher levels of physical activity reduce the risk 
of diabetes by 28%  
https://en.wikipedia.org/wiki/Diabetes_mellitus#Prevention 
Prophylaxis 2  
• Dietary changes known to be effective in 
helping to prevent diabetes include 
maintaining a diet rich in whole grains and 
fiber, and choosing good fats, such as 
the polyunsaturated fats found in nuts, 
vegetable oils, and fish 
• The relationship between type 2 DM and the 
main modifiable risk factors (excess weight, 
unhealthy diet, physical inactivity and tobacco 
use) is similar in all regions of the world  
https://en.wikipedia.org/wiki/Diabetes_mellitus#Prevention 
Abbreviations  
BUN - blood urea nitrogen test 
CGMs  - continuous glucose monitors 
DKA    - diabetic ketoacidosis 
DM     - diabetes mellitus 
GDM  - Gestational diabetes mellitus 
GIP     - glucose-dependent 
insulinotropic polypeptide  
GLP-1 - the postprandial glucagonlike 
peptide-1 
HbA1c - Glycated Hemoglobin A1c 
HLA    - human leukocyte antigen 
HONK - hyperosmolar nonketotic 
state 
IGT      - impaired glucose tolerance 
IFG      - impaired fasting glucose 
IU         - international unit of insulin 
NYHA  - New York Heart Association 
OGTT  - oral glucose tolerance test 
SGLT-2 - Sodium-glucose co-
transporter 2  
SNPs   - single-nucleotide 
polymorphisms 
WHO  - World Health Organization 
 
Diagnostic and treatment guidelines 
• IDF Clinical Practice Guidelines 
• Type 2 diabetes in adults: management 
• Diabetes in pregnancy: management from 
preconception to the postnatal period 
• Guidelines on diabetes, pre-diabetes, and 
cardiovascular diseases 
• Managing older people with type 2 diabetes: 
global guidelines(external link) 
 
 
